In May 2026, the company reported positive Phase II/III trial results for its investigational next-gen immune drug TAK-881 (immune globulin subcutaneous (human), 20% solution (SCIG 20%) with recombinant human hyaluronidase), which showed comparable efficacy, safety and immune protection to its existing lower dose immune globulin therapy HyQvia (immune globulin infusion (human) 10% with recombinant human hyaluronidase) in primary immunodeficiency disease, while offering the potential for lower infusion volumes and shorter treatment times.
TABLE 5 The application of NAC in tissue engineering biomaterials
What might have taken a week of sunbathing to achieve before can now be accomplished in a fraction of the time
Individual results vary, and no specific outcome is guaranteed
The medium was refreshed daily throughout the 5-day differentiation period
Some participants appeared to respond earlier, while others saw more meaningful changes emerge between weeks 6 and 8 as the effects continued to build over time
